Compare Bristol-Myers Squibb Co (BMY) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Altria Group Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.95 (market cap $116.30B), while Altria Group Inc trades at $70.35 (market cap $117.16B). The key difference: Bristol-Myers Squibb Co and Altria Group Inc are close in size by market cap, and Altria Group Inc pays the higher dividend (6.04%). Which is the better fit depends on your goals.
| BMY | MO | |
|---|---|---|
Market Cap | $116.30B | $117.16B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $74.55 |
52-Week Low | $42.60 | $54.72 |
Enterprise Value | $152.24B | $138.23B |
Dividend Yield | 4.42% | 6.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
MO trades at $71.87, up 0.14% today, with a neutral technical signal and bullish moving averages. The company reported a net income margin of 39.52% for 2025, with recent earnings beating expectations in Q1 2026. Strong cash flow from operations of $9.29B supports its dividend, with a recent $1.06 payment declared. Analyst consensus is bullish with a $71.00 price target.
Outlook remains stable with defensive qualities highlighted by media, but risks include high debt levels and regulatory pressures. The stock offers a high yield and pricing power, though revenue trends show slight volatility. Investment appeal centers on dividend sustainability and cash flow generation amid a challenging industry backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
